Abstract
Objective: Investigate effects of aspirin/dipyridamole and aspirin on blood viscosity (BV) in subjects with hyperhomocystememia (>14 μmol/L) and stable cardiovascular disease (CVD) or ≥ 20% risk for CVD were the aims of this study. Method: Forty‐seven subjects were treated with 14 days of either aspirin/dipyridamole (25 mg/200 mg twice‐daily) or aspirin (81 mg daily). BV was measured from fasting specimens at 37°C from whole blood at shear rates ranging from 1,000 to 1s−1 by using a scanning capillary viscometer (Rheolog™ Rheologics Inc., Exton, Pennsylvania, USA). Results: Aspirin/dipyridamole was more effective than aspirin therapy in reducing BV at shear rates of 1 s−1 (−3.03 [−3.88, −2.17] mPas vs. −0.07 [−1.06, 0.92] mPas; P−1 (−1.86 [−2.72, −1.01] mPas vs. −0.21 [−1.20, 0.79] mPas; P=0.0136); however, there were no significant differences in blood viscosity at shear rates of 5 s−1 to 1000 s−1. Changes in hematocrit, a major determinant of whole BV, were greater in the aspirin/dipyridamole group than the aspirin group (P=0.043). After hematocrit adjustment, differences in BV between aspirin/dipyridamole and aspirin remained significant at 1s−1 (−2.78 [−3.68, −1.88] mPas vs. −0.04 [−1.05, 0.98] mPas; P−1 (−1.62 [−2.52, −0.72] mPas vs. −0.17 [−1.19, 0.85] mPas; P=0.0315). Conclusion: These findings may have important clinical benefits in the CVD prevention and treatment due to the contribution of BV in tissue perfusion and thrombus formation.

This publication has 22 references indexed in Scilit: